Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ExeGi.

    Client Virtual Booth

    EXEGI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ExeGi
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    155 Gibbs St, Rockville, Maryland 20850
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://exegipharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/exegi-pharma-llc-/
    Twitter
    Twitter
    https://twitter.com/ExeGiPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346

    Details:

    ExeGi investigational product candidate EXE-346, which is a microbiome modulator probiotic. Currently, it is being evaluated in the Phase I/II clinical trial studies for the treatment of excessive stool frequency in patients with an ileal pouch-anal anastomosis.


    Lead Product(s): EXE-346

    Therapeutic Area: Gastroenterology Product Name: EXE-346

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 08, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE-346 a Live Biotherapeutic Biologic Drug

    Details:

    EXE-346 is a live biotherapeutic product (LBP) a blend of probiotic bacteria formulated in extremely high potency. The product is currently under development to manage excessive stool frequency in patients who have undergone an ileal pouch-anal anastomosis (IPAA).


    Lead Product(s): EXE-346

    Therapeutic Area: Gastroenterology Product Name: EXE-346

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 26, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ExeGi Pharma Announces FDA Orphan Drug Designation for EXE-346 Live Biotherapeutic

    Details:

    EXE-346 is an LBP which contains a fixed-proportion of 8 strains of live probiotic bacteria which are intended for oral administration. EXE-346 is intended to decrease this inflammation of the pouch and prevent active disease flare-ups.


    Lead Product(s): EXE-346

    Therapeutic Area: Immunology Product Name: EXE-346

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 12, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes

    Details:

    Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients.


    Lead Product(s): Live Biotherapeutic Product,Hydroxychloroquine Sulphate,Antibiotics

    Therapeutic Area: Infections and Infectious Diseases Product Name: SivoBiome

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 13, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search